AI assistant
Alkermes plc. — Director's Dealing 2026
Jan 8, 2026
31048_dirs_2026-01-08_dc6bda1e-9efe-4012-9001-29278ae39e2c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Alkermes plc. (ALKS)
CIK: 0001520262
Period of Report: 2026-01-08
Reporting Person: Hopkinson Craig C. (EVP R&D, Chief Medical Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2026-01-08 | Ordinary Shares | M | 5000 | $19.34 | Acquired | 66740 | Direct |
| 2026-01-08 | Ordinary Shares | S | 5000 | $30.001 | Disposed | 61740 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2026-01-08 | Employee Stock Option (Right to Buy) | $19.34 | M | 5000 | Disposed | 2031-02-22 | Ordinary Shares (5000) | Direct |
Footnotes
F1: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025.
F2: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025.
F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.00 to $30.01. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request.
F4: These options are fully vested in accordance with their terms.